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Agreat number of studies in various populations have suggested an association between several single-nucleotide polymorphisms (SNPs) and type 2 diabetes. For example, transcription factor 7-like 2 (*TCF7L2*) is a highly reliable predisposing gene for type 2 diabetes ([@r1]--[@r3]). In addition, recent genome-wide association studies (GWASs) have provided new susceptible loci for type 2 diabetes ([@r4]--[@r10]). A GWAS in French subjects, for example, identified rs13266634, a nonsynonymous SNP (R325W) on the solute carrier family 30 member 8 (*SLC30A8*) gene, as a polymorphism involved in type 2 diabetes susceptibility ([@r4]). The study also reported an association between type 2 diabetes and rs1111875, as well as rs7923837, located in the hematopoietically expressed homeobox gene (*HHEX*). These associations were replicated in three independent GWASs in various populations ([@r5]--[@r7]).

Additional susceptible SNPs were independently identified in the insulin-like growth factor 2 mRNA-binding protein 2 gene (*IGF2BP2*, rs4402960, and rs1470569) ([@r5],[@r6]). Involvement of SNPs rs10811661, located upstream of cyclin-dependent kinase inhibitor genes *CDKN2A* and *CDKN2B*, and "rs7754840/rs7756992," located in the CDK5 regulatory subunit-associated protein 1-like 1 gene (*CDKAL1*), has also been suggested ([@r5],[@r6],[@r8],[@r9]). A recent population-based study in Danish subjects replicated the susceptible association of *HHEX* rs111875, *CDKN2A/B* rs10811661, and *IGF2BP2* rs4402960 with type 2 diabetes ([@r10]).

Findings from previous GWASs, however, cannot be extrapolated to other populations with different lifestyles and environmental backgrounds. In particular, the genetic background for type 2 diabetes development in East Asians, who show lower basal insulin secretion and a marked decrease in insulin release in response to development of glucose tolerance ([@r11]), appears to be different from that in Caucasians or individuals of European origin. Further, SNP frequency differences are suggested to be an additional factor influencing type 2 diabetes susceptibility.

Here, based on a recent GWAS ([@r4]--[@r10]), we conducted a replication study of candidate SNPs associated with type 2 diabetes in Japanese diabetic subjects, as well as in a general Japanese population sample.

RESEARCH DESIGN AND METHODS
===========================

Case and control subjects.
--------------------------

Basic clinical characteristics of subjects are summarized in Supplemental Table 1 (located in an online appendix at <http://dx.doi.org/10.2337/db07-1785>). All type 2 diabetic subjects (*n* = 506) were inpatients or outpatients evaluated by diabetes specialists at Ehime University Hospital and Ehime Prefectural Hospital in Japan. Diabetes was diagnosed based on the 1998 American Diabetes Association criteria ([@r12]). Nondiabetic control subjects (*n* = 402) were chosen based on the absence of a history of diabetes in the subject and among first-degree relatives, as well as either normal glucose tolerance, confirmed by a 75-g oral glucose tolerance test, or A1C levels \<5.6 with fasting plasma glucose levels \<110 mg/dl. All case and control subjects were native Japanese. Selection criteria details have been described in a previous study ([@r13]). A total of 139 type 2 diabetic patients and 136 control subjects were overlapped with the previous meta-analysis for TCF7L2 polymorphisms ([@r14]).

General population.
-------------------

The general population subjects were selected from residents of a community of 11,000 inhabitants in Ehime Prefecture, a largely rural area located in western Japan ([@r15]). Subjects were recruited through a community-based annual medical checkup process for self-employees, including farmers and foresters, employees of small companies, and elderly without fixed employment. The sample population consisted of 1,963 middle-aged to elderly residents (Supplemental Table 2). Overnight fasting plasma samples for the measurement of plasma insulin concentrations were available for all sample subjects. Baseline clinical characteristics were obtained from personal health records evaluated during the medical checkup. All study procedures were approved by the ethics committee of the Ehime University Graduate School of Medicine, and informed consent was obtained from each participating subject.

Genotyping.
-----------

Genomic DNA was extracted from peripheral blood (QIAamp DNA blood kit; QIAGEN, Hilden, Germany). All SNPs were analyzed by TaqMan probe assay (Applied Biosystems, Foster City, CA) using commercially available primers and probes purchased from the Assay-on-Demand system (Supplemental Table 3).

Statistical analysis.
---------------------

Data are expressed as means ± SD. Linkage disequilibrium was assessed using the Haploview software (Broad Institute, Cambridge, MA) ([@r16]). Frequency differences in each genotype were assessed by the χ^2^ test. The pooled odds ratios for allele frequency with those of six other association studies in Japanese ([@r17]--[@r22]) were estimated using the fixed-effects model (Mantel-Haenszel method). Differences in plasma insulin levels among genotypes (ANOVA and multiple regression analysis \[additive model\] adjusted for age, sex, and BMI) were assessed using a commercially available statistical software package (SPSS Version 14.0; SPSS, Chicago, IL). Current treatment of hyperglycemia was further adjusted in type 2 diabetic patients when appropriate. Null hypotheses were rejected at a level of significance of *P* \< 0.05.

RESULTS
=======

[Table 1](#t1){ref-type="table"} summarizes the association between 11 candidate SNPs and type 2 diabetes in case-control subjects. The T allele of *TCF7L2* (rs12255372) was significantly associated with type 2 diabetes. A tendency to association was also observed with SNP rs7903146, which was in linkage disequilibrium with rs12255372 (D′ = 0.854, *r*^2^ = 0.421). However, the risk allele frequency of these SNPs was considerably low, which is in agreement with previous reports in Japanese subjects ([@r17],[@r18]). The post hoc calculated statistical power of these SNPs (allele frequency) was 36.1% and 25.4% for rs12255372 and rs7903146, respectively, with a 5% type 1 error rate.

In addition to *TCF7L2* polymorphisms, a significant association was observed between type 2 diabetes and polymorphisms in *CDKAL1* (rs7756992 \[power: 51.0%\], rs7754840 \[52.9%\]; D′ = 0.920; *r*^2^ = 0.648), *HHEX* (rs7923837 \[30.4%\]), *IGF2BP2* (rs4402960 \[31.3%\], rs1470579 \[51.1%\]; D′ = 0.997; *r*^2^ = 0.918), *CDKN2A/B* (rs10811661 \[32.6%\]), and *SLC30A8* (rs13266634 \[10.7%\]), but not *HHEX* (rs1111875 \[8.5%\]). Further, a marginally significant association was observed between type 2 diabetes and the *KCNJ11* polymorphism (rs5219 \[21.8%\])). Compared with control subjects of European descent, risk allele frequencies in Japanese control subjects were higher in the *CDKAL1* gene (rs7756992 G allele, 0.470 vs. 0.258) and lower in the *HHEX* (rs1111875 C allele, 0.288 vs. 0.598; rs7923837 G allele, 0.177 vs. 0.597), *CDKN2A/B* (rs10811661 T allele, 0.555 vs. 0.850), *SLC30A8* (rs13266634 C allele, 0.568 vs. 0.699), and *KCNJ11* (rs5219 T allele, 0.372 vs. 0.464) genes ([@r4],[@r6],[@r8]). In contrast, no significant frequency differences were observed in the *CDKAL1* rs7754840 (C allele, 0.399 vs. 0.360) and *IGF2BP2* rs4402960 (T allele, 0.287 vs. 0.304) polymorphisms.

However, except for the *CDKAL* polymorphisms, statistical significance was not reached in the observed associations using Bonferroni\'s correction, possibly due to limited statistical power. To further clarify type 2 diabetes susceptibility, seven association studies in Japanese subjects ([@r17]--[@r22]), including our present data, were meta-analyzed ([Fig. 1](#f1){ref-type="fig"}). Type 2 diabetes susceptibility was confirmed in all analyzed polymorphisms, both before and after Bonferroni\'s adjustment. Further, two SNPs (rs1111875 in *HHEX* and rs5219 in *KCNJ11*), which were not replicated in our data, were confirmed as susceptible polymorphisms for type 2 diabetes.

To further clarify the pathophysiological significance of the susceptibility of these seven genes for type 2 diabetes, associations with plasma insulin levels were evaluated in a community-derived population sample ([Table 2](#t2){ref-type="table"}). Although differences in plasma insulin levels among the *CDKAL1* rs7756992 genotype did not reach statistical significance, probably due to the limited statistical power (post hoc calculated statistical power: 28.3% for type 2 diabetic patients, 31.8% for control subjects), multiple regression analysis involving the genotype as an additive model showed significantly lower insulin levels in type 2 diabetic subjects with risk genotypes after adjusting for age, sex, and BMI. The association of *CDKAL1* rs7756992 remained significant after further adjustment for the current treatment of hyperglycemia (*n* = 67, *P* = 0.021). The risk allele of *CDKAL1* rs7754840 also tended to be associated with lower insulin levels. However, no significant associations were observed in other SNPs.

DISCUSSION
==========

In the present study, we replicated the associations of several candidate genes derived from a recent GWAS ([@r4]--[@r10]). However, several conflicting results were observed with other replication studies in Japanese diabetic patients. Horikoshi et al. ([@r21]) and Furukawa et al. ([@r20]) observed a markedly strong association between type 2 diabetes and variants of *HHEX* rs1111875, whereas no association was observed in our study. However, results of our meta-analysis ([Fig. 1](#f1){ref-type="fig"}) clearly indicate the type 2 diabetes susceptibility of all candidate genes, including *HHEX* rs1111875. Conservation of susceptible loci for type 2 diabetes was independent of ethnic background.

However, the attributable risk of these SNPs susceptible for type 2 diabetes was different from that of European ancestries. For example, the pooled odds ratios of the *TCF7L2* gene polymorphisms were slightly higher than those in European ancestries ([@r6],[@r23]), whereas the risk allele frequencies were considerably lower. Alternatively, for *HHEX* gene polymorphisms, odds ratios were slightly higher in Japanese ([@r7]). Very recently, genome-wide screening in a Japanese population identified the *KCNQ1* gene polymorphism as a new susceptible loci for type 2 diabetes ([@r24]). These authors reported that the risk alleles of rs2237892 and other SNPs in linkage disequilibrium with rs2237892 were associated with an increased risk of type 2 diabetes. However, apparent associations of the *KCNQ1* SNPs were not observed in previous GWAS in populations of European descent ([@r4]--[@r10]). This discrepancy may be due mainly to the differences in allele frequencies of the susceptible SNPs.

It has been suggested that several candidate SNPs identified from genome-wide screening contribute to diabetes susceptibility primarily through effects on insulin secretion. In our quantitative trait analysis in a general Japanese population, we observed lower basal plasma insulin levels in type 2 diabetic patients carrying the risk genotype of *CDKAL1* rs7756992 SNP. Although the function of the *CDKAL1* gene product is unknown, one study suggested that CDKAL1 has a role in the inhibition of cyclin-dependent kinase 5 (CDK5) activity in pancreatic β-cells ([@r8]), which prevents a decrease in insulin gene expression resulting from glucotoxicity. That study also observed reduced insulin secretion in response to glucose loading in homozygous carriers of the *CDKAL1* rs7756992 polymorphism risk allele ([@r8]). Pascoe et al. ([@r25]) also reported lower insulin secretion after glucose loading in risk allele carriers of another SNP of the *CDKAL1* gene. Our study is the first to show a possible association between this SNP and basal insulin levels in type 2 diabetic patients. This observation provides supporting evidence for the pathophysiological role of the *CDKAL1* gene products in the progression of type 2 diabetes, as well as the disease susceptibility of this genetic variant.

Several limitations of this study warrant mention. First, differences in linkage disequilibrium between Japanese and European subjects means that tracking of the causal variants may not be possible in SNPs based on the association study in European ancestries. Although our meta-analysis showed an association between type 2 diabetes susceptibility and the analyzed candidate SNPs, causal variants may also be strongly represented by other SNPs in Japanese subjects. Studies with multiple tag-SNPs at loci chosen based on the linkage disequilibrium pattern in Japanese may provide further clarification of this issue. Second, we did not investigate the class of antihyperglycemic drugs, including insulin treatment, in the general population sample. Although each drug may have affected fasting plasma insulin differently, association of the *CDKAL1* genotype with plasma insulin levels was statistically significant after further adjustment for current treatment for hyperglycemia.

In the present study, we replicated several genetic variants as risk markers for type 2 diabetes susceptibility in Japanese by performing a case-control analysis and meta-analysis. These findings may be useful in advanced clinical practice and public health genomics.
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###### 

Association of candidate SNPs with type 2 diabetes in case and control subjects

  Gene (rs number)        Type 2 diabetes frequency   Risk allele   Hardy-Weinberg equilibrium (*P*) (control)   Allele                 Dominant   Recessive              Additive (*P*)                                         
  ----------------------- --------------------------- ------------- -------------------------------------------- ---------------------- ---------- ---------------------- ---------------- ---------------------- -------------- --------------
                          Control                                                                                                                                                                                                
  TCF7L2 (rs12255372)     TT/TG/GG                    T             0.721                                                                                                                                                        
                          1/33/453                                                                               2.082 (1.112--3.898)   0.022      2.059 (1.089--3.893)   0.026            --                     --             0.065
                          0/14/384                                                                                                                                                                                               
  TCF7L2 (rs7903146)      TT/TC/CC                    T             0.501                                                                                                                                                        
                          2/45/434                                                                               1.589 (0.978--2.582)   0.061      1.549 (0.941--2.551)   0.085            --                     --             0.132
                          0/26/372                                                                                                                                                                                               
  CDKAL1 (rs7756992)      GG/GA/AA                    G             0.053                                                                                                                                                        
                          155/217/119                                                                            1.307 (1.084--1.577)   0.005      1.081 (0.796--1.467)   0.618            1.887 (1.381--2.578)   6.8 × 10^−5^   2.0 × 10^−4^
                          78/217/102                                                                                                                                                                                             
  CDKAL1 (rs7754840)      CC/CG/GG                    C             0.189                                                                                                                                                        
                          117/225/149                                                                            1.321 (1.093--1.596)   0.004      1.209 (0.912--1.604)   0.187            1.866 (1.316--2.645)   4.6 × 10^−4^   0.002
                          57/203/137                                                                                                                                                                                             
  HHEX (rs1111875)        CC/CT/TT                    C             0.593                                                                                                                                                        
                          44/211/235                                                                             1.086 (0.885--1.334)   0.430      1.141 (0.876--1.488)   0.328            1.018 (0.639--1.620)   0.942          0.602
                          35/158/203                                                                                                                                                                                             
  HHEX (rs79203837)       GG/GA/AA                    G             0.381                                                                                                                                                        
                          17/178/295                                                                             1.286 (1.015--1.630)   0.037      1.432 (1.085--1.891)   0.011            0.920 (0.454--1.866)   0.817          0.026
                          15/111/273                                                                                                                                                                                             
  IGF2BP2 (rs4402960)     TT/TG/GG                    T             0.972                                                                                                                                                        
                          66/196/231                                                                             1.239 (1.011--1.517)   0.039      1.175 (0.902--1.530)   0.232            1.714 (1.103--2.663)   0.016          0.050
                          33/163/203                                                                                                                                                                                             
  IGF2BP2 (rs1470579)     CC/CA/AA                    C             0.940                                                                                                                                                        
                          77/198/216                                                                             1.334 (1.091--1.630)   0.005      1.260 (0.967--1.643)   0.087            1.929 (1.263--2.947)   0.002          0.007
                          35/165/198                                                                                                                                                                                             
  CDKN2A/B (rs10811661)   TT/TC/CC                    T             0.394                                                                                                                                                        
                          189/222/85                                                                             1.227 (1.016--1.482)   0.034      1.116 (0.792--1.572)   0.531            1.454 (1.098--1.925)   0.009          0.031
                          119/206/75                                                                                                                                                                                             
  SLC30A8 (rs13266634)    CC/CT/TT                    C             0.395                                                                                                                                                        
                          162/259/72                                                                             1.103 (0.913--1.332)   0.311      1.439 (1.103--2.044)   0.042            0.983 (0.742--1.300)   0.902          0.090
                          133/188/79                                                                                                                                                                                             
  KCNJ11 (rs5219)         TT/TC/CC                    T             0.302                                                                                                                                                        
                          83/232/169                                                                             1.181 (0.974--1.432)   0.090      1.156 (0.878--1.523)   0.301            1.436 (0.983--2.099)   0.061          0.154
                          50/195/152                                                                                                                                                                                             

*n* = 908. Type 2 diabetes is defined by fasting blood glucose ≥126 mg/dl, or occasional blood glucose ≥200 mg/dl and/or current use of antidiabetic agents. Differences in genotype frequency between diabetic patients and normal control subjects, as well as deviations from the Hardy-Weinberg equilibrium in control subjects, were assessed using the χ^2^ test.

###### 

Association of candidate SNPs with plasma insulin levels in the general population sample

  Gene (rs number)                                       Risk allele (T)   Plasma insulin (μU/ml)   *P*                                                              
  ------------------------------------------------------ ----------------- ------------------------ --------- ----------- --------- ------------- ---------- ------- -------
  TCF7L2[\*](#t2fn1){ref-type="table-fn"} (rs12255372)                                                                                                               
      Control                                                              5.5 ± 2.7                \(2\)     6.2 ± 4.7   \(52\)    6.5 ± 4.8     (1,770)    0.661   0.749
      Type 2 diabetes                                                      ---                      \(0\)     4.2 ± 1.0   \(3\)     9.0 ± 7.3     \(136\)    0.256   0.368
  TCF7L2[\*](#t2fn1){ref-type="table-fn"} (rs7903146)    T                 TT                                 TC                    CC                               
      Control                                                              6.8                      \(1\)     6.5 ± 4.3   \(111\)   6.5 ± 4.8     (1,712)    0.967   0.336
      Type 2 diabetes                                                      ---                      \(0\)     5.1 ± 2.3   \(8\)     9.1 ± 7.4     \(131\)    0.130   0.226
  CDKAL1 (rs7756992)                                     G                 GG                                 GA                    AA                               
      Control                                                              6.3 ± 5.2                \(428\)   6.5 ± 4.6   \(895\)   6.6 ± 4.7     \(501\)    0.227   0.457
      Type 2 diabetes                                                      7.9 ± 7.0                \(38\)    8.8 ± 6.3   \(75\)    10.7 ± 10.0   \(26\)     0.269   0.020
  CDKAL1 (rs7754840)                                     C                 CC                                 CG                    GG                               
      Control                                                              6.1 ± 4.7                \(315\)   6.4 ± 4.8   \(868\)   6.7 ± 4.7     \(641\)    0.083   0.157
      Type 2 diabetes                                                      7.1 ± 5.1                \(32\)    9.0 ± 6.5   \(67\)    10.3 ± 9.4    \(40\)     0.154   0.097
  HHEX (rs1111875)                                       C                 CC                                 CT                    TT                               
      Control                                                              6.4 ± 4.6                \(185\)   6.4 ± 4.4   \(755\)   6.6 ± 5.1     \(884\)    0.867   0.883
      Type 2 diabetes                                                      9.8 ± 11.6               \(15\)    7.7 ± 5.2   \(62\)    9.9 ± 7.7     \(62\)     0.323   0.470
  HHEX (rs7923837)                                       G                 GG                                 GA                    AA                               
      Control                                                              6.1 ± 4.1                \(112\)   6.5 ± 4.9   \(692\)   6.5 ± 4.7     \(1020\)   0.818   0.749
      Type 2 diabetes                                                      7.3 ± 4.6                \(9\)     8.8 ± 6.9   \(56\)    9.1 ± 7.8     \(74\)     0.811   0.789
  IGF2BP2 (rs4402960)                                    T                 TT                                 TG                    GG                               
      Control                                                              6.2 ± 3.9                \(215\)   6.7 ± 5.2   \(767\)   6.3 ± 4.5     \(842\)    0.276   0.308
      Type 2 diabetes                                                      12.2 ± 10.0              \(15\)    7.8 ± 5.4   \(72\)    9.5 ± 8.4     \(52\)     0.186   0.843
  IGF2BP2 (rs1470579)                                    C                 CC                                 CA                    AA                               
      Control                                                              6.1 ± 3.8                \(239\)   6.8 ± 5.2   \(781\)   6.3 ± 4.5     \(804\)    0.118   0.314
      Type 2 diabetes                                                      11.6 ± 9.6               \(17\)    7.8 ± 5.4   \(72\)    9.5 ± 8.5     \(50\)     0.276   0.869
  CDKN2A/B (rs10811661)                                  T                 TT                                 TC                    CC                               
      Control                                                              6.4 ± 4.7                \(591\)   6.5 ± 4.6   \(886\)   6.6 ± 5.2     \(347\)    0.719   0.858
      Type 2 diabetes                                                      8.1 ± 8.0                \(41\)    8.9 ± 6.5   \(72\)    10.2 ± 8.0    \(26\)     0.346   0.169
  SLC30A8 (rs13266634)                                   C                 CC                                 CT                    TT                               
      Control                                                              6.5 ± 4.9                \(671\)   6.4 ± 4.4   \(847\)   6.6 ± 5.2     \(306\)    0.939   0.910
      Type 2 diabetes                                                      9.8 ± 7.1                \(51\)    7.9 ± 5.6   \(68\)    9.8 ± 11.5    \(20\)     0.151   0.332
  KCNJ11 (rs5219)                                        T                 TT                                 TC                    CC                               
      Control                                                              6.5 ± 4.8                \(222\)   6.3 ± 4.6   \(836\)   6.7 ± 4.9     \(766\)    0.088   0.156
      Type 2 diabetes                                                      6.8 ± 3.8                \(28\)    8.8 ± 7.2   \(68\)    10.3 ± 8.7    \(43\)     0.144   0.205

Data are means ± SD. *n* = 1,963. Number of subjects in each genotype is provided in parentheses. Statistical significance was assessed using log-transformed insulin value. Multiple regression analysis involving each genotype as an additive model adjusted for age, sex, and BMI.

T allele dominant model.
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